Consumers claim drug Abilify caused compulsive behaviors

By Noddy A. Fernandez | May 25, 2018

SAN FRANCISCO – Several individuals allege a prescription drug caused them to engage in compulsive behaviors.

SAN FRANCISCO – Several individuals allege a prescription drug caused them to engage in compulsive behaviors.

Bernard Adeniran, Everarda Aispuro, Alma Alford, Daniel Andrews, et al. filed a complaint on May 2 in the San Francisco County Superior Court against Bristol-Myers Squibb Co., McKesson Corp., Otsuka America Pharmaceutical Inc., Otsuka Pharmaceutical Co. LTD and Does 1 to 100 alleging strict liability, negligence, fraudulent concealment and other counts.

According to the complaint, the defendants manufacture, promote and sell prescription drug Abilify to treat depression, schizophrenia and other disorders. The plaintiffs allege Abilify injured them by causing harmful compulsive behaviors such as compulsive gambling, compulsive shopping and hyper-sexuality. 

The plaintiffs claim the defendants did not warn, advise or educate, otherwise inform users or prescribers in the U.S. about the risks of compulsive behavior associated with the drug.

The plaintiffs request a trial by jury and seek judgment for actual damages, pre- and post-judgment interest, punitive damages, costs, expenses, attorney's fees and for such further relief as the court deems necessary, just and proper. They are represented by Jennifer Liakos of Napoli Shkolnik PLLC in Los Angeles.

Superior Court of California - County of San Francisco case number CGC18566226

Want to get notified whenever we write about any of these organizations ?

Sign-up Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Bristol-Myers Squibb Superior Court of California - County of San Francisco

More News

The Record Network